Pharmacogenetics of statins: Achievements, whole-genome analyses and future perspectives

Iris Postmus, Jeffrey J.W. Verschuren, Anton J.M. De Craen, P. Eline Slagboom, Rudi G.J. Westendorp, J. Wouter Jukema, Stella Trompet

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

Statins are the most commonly prescribed class of drug worldwide and therapy is highly effective in reducing low-density lipoprotein cholesterol levels and cardiovascular events. However, there is large variability in clinical response to statin treatment. Recent research provides evidence that genetic variation contributes to this variable response to statin treatment. Until recently, pharmacogenetic studies have used mainly candidate gene approaches to investigate these effects. Since candidate gene studies explain only a small part of the observed variation and results have often been inconsistent, genome-wide association (GWA) studies may be a better approach. In this paper the most important candidate gene studies and the first published GWA studies assessing statin response are discussed. Moreover, we describe the PHASE study, an EU-funded GWA study that will investigate the genetic variation responsible for the variation in response to pravastatin in a large randomized clinical trial.

Original languageEnglish
Pages (from-to)831-840
Number of pages10
JournalPharmacogenomics
Volume13
Issue number7
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Cardiovascular disease
  • Genome-wide association study
  • Lipid levels
  • Pharmacogenetics n statins

Fingerprint

Dive into the research topics of 'Pharmacogenetics of statins: Achievements, whole-genome analyses and future perspectives'. Together they form a unique fingerprint.

Cite this